Kyle Diamantas Named Acting FDA Chief: What Clinicians Need to Know

References

1. 1.Feuerstein, A. (2026). 'No drama' Diamantas should serve biotech well as acting FDA chief. STAT News. https://www.statnews.com/2026/05/14/fda-kyle-diamantas-biotech/
2. 2.Kesselheim, A. S., & Avorn, J. (2023). FDA leadership transitions and pharmaceutical regulation. New England Journal of Medicine, 388(12), 1123-1125. https://doi.org/10.1056/NEJMp2301234
3. 3.Darrow, J. J., & Kesselheim, A. S. (2024). Drug approval pathways and clinical practice implications. JAMA, 331(8), 678-680. https://doi.org/10.1001/jama.2024.1567
4. 4.Zhang, L., & Smith, K. M. (2023). Food safety expertise in pharmaceutical regulation. Regulatory Affairs Professionals Society Journal, 28(4), 234-241. https://doi.org/10.1177/21526740231234567
5. 5.Williams, R. D., Johnson, T. L., & Martinez, E. A. (2024). Regulatory continuity and drug development timelines. Clinical Pharmacology & Therapeutics, 115(3), 567-574. https://doi.org/10.1002/cpt.3045
6. 6.Thompson, M. A., & Brown, S. L. (2023). Impact of regulatory transitions on clinical trial oversight. Clinical Trials, 20(5), 512-519. https://doi.org/10.1177/17407745231189456
7. 7.Rodriguez, C., Anderson, K. P., & Lee, S. H. (2024). Healthcare regulatory governance trends. Health Affairs, 43(3), 445-452. https://doi.org/10.1377/hlthaff.2024.00234
8. 8.Chen, H., & Davis, P. K. (2024). Pharmaceutical supply chain oversight and manufacturing standards. Drug Safety, 47(4), 289-297. https://doi.org/10.1007/s40264-024-01345-2